Z. Xue

Most-cited papers

1. Inducing and exploiting vulnerabilities for the treatment of liver cancer

   Cun Wang, S. Vegna, Haojie Jin, Bente Benedict +21 more

   2019Nature374 citations Open access

   Semantic Scholar

   Save

2. Integration of genomic, transcriptomic and proteomic data identifies two biologically distinct subtypes of invasive lobular breast cancer

   M. Michaut, Suet-Feung Chin, I. Majewski, T. Severson +42 more

   2016Scientific Reports165 citations Open access

   Semantic Scholar

   Save

3. MAP3K1 and MAP2K4 mutations are associated with sensitivity to MEK inhibitors in multiple cancer models

   Z. Xue, D. Vis, A. Bruna, Tonći Šuštić +7 more

   2018Cell Research106 citations Open access

   Semantic Scholar

   Save

4. Phospho-ERK is a biomarker of response to a synthetic lethal drug combination of sorafenib and MEK inhibition in liver cancer.

   Cun Wang, Haojie Jin, Dongmei Gao, C. Lieftink +7 more

   2018Journal of Hepatology87 citations Open access

   Semantic Scholar

   Save

5. A CRISPR screen identifies CDK7 as a therapeutic target in hepatocellular carcinoma

   Cun Wang, Haojie Jin, Dongmei Gao, Liqin Wang +7 more

   2018Cell Research62 citations Open access

   Semantic Scholar

   Save

6. A regression model for estimating DNA copy number applied to capture sequencing data

   G. Rigaill, Sidney Cadot, R. Kluin, Z. Xue +3 more

   2012Bioinform.21 citations

   Semantic Scholar

   Save

7. Phospho-ERK is a response biomarker to a combination of sorafenib and MEK inhibition in liver cancer

   Cun Wang, Haojie Jin, Dongmei Gao, B. Evers +6 more

   2018bioRxiv3 citations Open access

   Semantic Scholar

   Save

8. 538 Finding New Signalling Pathways That Contribute to Cancer Pathogenesis

   I. Majewski, Z. Xue, L. Mittempergher, M. Michaut +6 more

   20121 citations

   Semantic Scholar

   Save